NOVARTIND.BO up 20.00% pre-market at INR 996.50: 21 Feb 2026 top gainer outlook

NOVARTIND.BO stock leads pre-market movers on 21 Feb 2026 after a strong jump to INR 996.50, up 20.00% from the previous close. The BSE-listed Novartis India Limited move comes on volume 1,034,308.00 shares, far above the average volume of 12,081.00, signaling heavy interest. Traders should note the intraday high at INR 996.50 and the day low at INR 904.00, with market cap at INR 24,604,379,211.00. We provide a concise NOVARTIND.BO stock analysis, Meyka AI grade, and a short forecast to frame risk and opportunity in the pre-market session.

Pre-market price action and why NOVARTIND.BO stock is a top gainer

NOVARTIND.BO stock is trading at INR 996.50 pre-market on BSE, showing a 20.00% rise versus the previous close of INR 830.45. This sharp move pairs with volume 1,034,308.00, a relative volume of 85.62, which confirms institutional or block activity. The one-day range is INR 904.00-996.50, and the stock has tested its yearly high of INR 1,099.90 earlier in the last 12 months.

Key intraday and fundamental stats for NOVARTIND.BO stock

Novartis India Limited (NOVARTIND.BO) shows EPS 39.42 and PE 25.28, with a current dividend per share of INR 25.00. The 50-day average price is INR 792.28 and the 200-day average is INR 893.65, indicating the recent price strength. Market cap stands at INR 24,604,379,211.00 and shares outstanding total 24,690,797.00.

Valuation and financial health: NOVARTIND.BO stock fundamentals

Novartis India lists a price-to-book ratio 3.17 and price-to-sales 7.08, reflecting premium valuation versus many peers in the Healthcare sector. The company has cash per share INR 250.01 and a very low debt-to-equity 0.01, supporting balance-sheet strength. Return on equity is 12.65%, and net profit margin is 27.97%, which underpins steady profitability despite the rich multiples.

Technical read and Meyka grading for NOVARTIND.BO stock

Technically, NOVARTIND.BO stock shows overbought signals: RSI 77.45 and MFI 97.77. Momentum indicators show MACD histogram 12.54 and ADX 25.87, implying a strong uptrend but stretched momentum. Meyka AI rates NOVARTIND.BO with a score of 74.21 out of 100 (B+, BUY). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Analyst outlook, forecasts and price targets for NOVARTIND.BO stock

Meyka AI’s forecast model projects a yearly target INR 929.31, a 3-year target INR 1,027.02, and a 5-year target INR 1,124.46. Compared with the current price INR 996.50, the yearly projection implies an -6.74% downside, while the 3-year view implies +3.06% upside. These model-based numbers reflect mean reversion in the near term and moderate longer-term appreciation.

Risks, sector context and trading strategy for NOVARTIND.BO stock

Healthcare sector performance is muted YTD, with the sector down 2.31% year-to-date, which can cap upside for NOVARTIND.BO stock. Key risks include multiple contraction from the current PE 25.28, and short-term profit taking given overbought technicals. Traders may prefer staged entries, using INR 904.00 as a short-term support level and INR 1,100.00 as a near resistance reference.

Final Thoughts

NOVARTIND.BO stock is a clear pre-market top gainer on 21 Feb 2026, trading at INR 996.50 with 20.00% intraday strength and unusually high volume 1,034,308.00. Fundamentals show healthy profitability with EPS 39.42 and ROE 12.65%, while valuation metrics (PE 25.28, PB 3.17) price in growth. Technically the stock is overbought, so short-term pullbacks are possible. Meyka AI’s forecast model projects a yearly level INR 929.31, implying -6.74% near-term downside, and a 3-year target INR 1,027.02, implying +3.06% upside. Meyka AI rates NOVARTIND.BO with a 74.21/100 (B+, BUY) grade based on benchmark, sector, metrics, and consensus. These forecasts are model-based projections and not guarantees. For traders, consider risk limits and staged exposure; for long-term investors, monitor earnings on 07 May 2026 and use any consolidation toward INR 890.00-920.00 as potential accumulation zones. See the company site Novartis India and the BSE quote for live updates BSE – Novartis India Limited for primary sources. Meyka AI provides this as an AI-powered market analysis platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.